Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.32 |
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
| ▸ | NOS2 | P35228 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11599113 | 0.89 | — | — | |
| SCHEMBL4443923 | 0.87 | — | — | |
| SCHEMBL11600898 | 0.87 | — | — | |
| SCHEMBL18677023 | 0.85 | — | — | |
| SCHEMBL8383932 | 0.84 | CA2 (0.35) | NOS3NOS1NOS2 | |
| SCHEMBL28271276 | 0.83 | — | — | |
| SCHEMBL9822328 | 0.83 | — | — | |
| SCHEMBL10613669 | 0.83 | TSHR (0.50) | TSHRMEN1KMT2A | |
| SCHEMBL24933273 | 0.79 | GABRP (0.40) | NOS3NOS1NOS2TSHRMEN1 | |
| SCHEMBL9562888 | 0.77 | TRPV1 (0.39) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12331111-B2 | Anti-MS4A4A antibodies and methods of use thereof | ALECTOR LLC (US) | 2025-06-17 | — | — | US | disclosed |
| US-12331112-B2 | Anti-MS4A4A antibodies and methods of use thereof | ALECTOR LLC (US) | 2025-06-17 | — | — | US | disclosed |
| US-12319734-B2 | Anti-TMEM106B antibodies and methods of use thereof | ALECTOR LLC (US) | 2025-06-03 | — | — | US | disclosed |
| US-20250092144-A1 | METHODS OF USE OF ANTI-SORTILIN ANTIBODIES FOR TREATING A DISEASE, DISORDER, OR INJURY | ALECTOR LLC (US) | 2025-03-20 | — | — | US | disclosed |
| US-12215149-B2 | Anti-MS4A6A antibodies and methods of use thereof | ALECTOR LLC (US) | 2025-02-04 | — | — | US | disclosed |
| US-20240309097-A2 | METHODS OF USE OF ANTI-SORTILIN ANTIBODIES FOR TREATING A DISEASE, DISORDER, OR INJURY | ALECTOR LLC (US) | 2024-09-19 | — | — | US | disclosed |
| US-20240174746-A1 | ANTI-TMEM106B ANTIBODIES AND METHODS OF USE THEREOF | HERCULES CAPITAL, INC., AS AGENT | 2024-05-30 | — | — | US | disclosed |
| EP-4308606-A1 | ANTI-TMEM106B ANTIBODIES AND METHODS OF USE THEREOF | Alector LLC (US) | 2024-01-24 | — | — | EP | disclosed |
| US-20230303681-A1 | ANTI-TMEM106B ANTIBODIES AND METHODS OF USE THEREOF | ALECTOR LLC | 2023-09-28 | — | — | US | disclosed |
| US-20230142579-A1 | ANTI-MS4A4A ANTIBODIES AND METHODS OF USE THEREOF | ALECTOR LLC | 2023-05-11 | — | — | US | disclosed |
| US-20220380455-A1 | ANTI-MS4A6A ANTIBODIES AND METHODS OF USE THEREOF | HERCULES CAPITAL, INC., AS AGENT | 2022-12-01 | — | — | US | disclosed |
| US-11472874-B2 | Anti-MS4A4A antibodies and methods of use thereof | ALECTOR LLC (US) | 2022-10-18 | — | — | US | disclosed |
| WO-2022197947-A1 | ANTI-TMEM106B ANTIBODIES AND METHODS OF USE THEREOF | ALECTOR LLC (US) | 2022-09-22 | — | — | WO | disclosed |
| US-11440957-B2 | Anti-TMEM106B antibodies and methods of use thereof | ALECTOR LLC (US) | 2022-09-13 | — | — | US | disclosed |
| US-20220251219-A1 | METHODS OF USE OF ANTI-SORTILIN ANTIBODIES FOR TREATING A DISEASE, DISORDER, OR INJURY | ALECTOR LLC (US) | 2022-08-11 | — | — | US | disclosed |
| US-20220185899-A1 | METHODS OF INCREASING PROGRANULIN LEVELS USING ANTI-SORTILIN ANTIBODIES | ALECTOR LLC (US) | 2022-06-16 | — | — | US | disclosed |
| US-11339223-B2 | Methods of use of anti-Sortilin antibodies for treating a disease, disorder, or injury | ALECTOR LLC (US) | 2022-05-24 | — | — | US | disclosed |
| EP-3991748-A2 | ANTI-SORTILIN ANTIBODIES AND METHODS OF USE THEREOF | Alector LLC (US) | 2022-05-04 | — | — | EP | disclosed |